89 results about "Bacillus infections" patented technology

Compositions including a non-pathogenic lactic acid-producing bacteria, such as a Bacillus species, spores or an extracellular product of B. coagulans, formulated for oral administration to the intestinal tract for inhibiting bacterial gastrointestinal infections are described. Methods and systems using the compositions for treating gastrointestinal infections, particularly sudden infant death syndrome (SIDS) are also disclosed.

The invention discloses a reagent for detecting tubercle bacillus infection in vitro and a method thereof. The reagent comprises M233 polypeptide represented by SEQ ID No.1; and cytokine released from T cells is detected by contacting the M233 polypeptide or an analog thereof with the T cells of a tubercle bacillus host to determine whether the T cells identify the M233 polypeptide or the analog thereof. The reagent has the advantages of high sensitivity, good specificity, being free from interference of BCG vaccine and non-tuberculosis mycobacteria vaccine, being capable of detecting active pulmonary tuberculosis patients, the patients with dormant infection and healthy persons who contact with mycobacterium nontuberculosis. The reagent and the method are especially applicable to detecting tuberculosis and/or dormant infection thereof for Chinese people.

The present invention is compositions and methods for producing anti-bacterial polypeptides, and for using those compositions and methods for treating diseases and conditions caused by a bacterial infection. More specifically, the compositions and methods include treating a gram-negative bacterium with a gram-positive host that produces a polypeptide effective against the gram-negative bacterium.

A composition for treatment of bacterial infections of the eye is disclosed which comprises a lytic enzyme composition specific for the infecting bacteria, and a carrier for delivering said lytic enzyme.. The carrier for delivering at least one lytic enzyme to the eye may be but is not limited to the use of an isotonic solution..

The invention belongs to the technical field of veterinary biology, and particularly relates to a colon bacillus outer membrane protein monoclonal antibody and a preparation method and an application thereof. The antibody is prepared by taking cloned, expressed and purified taking avian pathogenic escherichia coli 78 (APECO78) outer membrane protein as an antigen immune BALB/c mouse with a hybrid tumor technology. The antibody has high specificity and high sensitivity, and an experimental basis is laid for future rapid and specific detection of colon bacillus infection with an immunology method. Meanwhile, as proved by an experiment, the monoclonal antibody disclosed by the invention has high neutralizing activity and protecting efficiency on colon bacillus infection of the same type, and can be used for preventing colibacillosis.

The invention provides a mosaic gene, which comprises a gene for coding tubercle bacillus protein Ag85a and a gene which is mosaiced at a Kpn I recognition sequence at sites 245-250 and/or an Acc I recognition sequence at sites 430-435 of Ag85a gene for coding the tubercle bacillus protein Ag85b. The invention provides a mosaic gene-containing mosaic tubercle bacillus gene vaccine, wherein the Ag85a gene is connected to a eukaryotic expression vector. The invention also provides a preparation method of the mosaic tubercle bacillus gene vaccine. The method comprises the following steps of: performing PCR (Polymerase Chain Reaction) amplification on an Ag85b gene segment; inserting the amplified Ag85b gene segment into the Ag85b gene-containing eukaryotic expression vector; and connecting by using ligase. The mosaic tubercle bacillus gene vaccine can be used for treating drug-resistant tubercle bacillus infection and can also be used in combination with levamisole serving as an adjuvantto induce stronger anti-tubercular cell immunological response.

The present invention is compositions and methods for producing anti-bacterial polypeptides, and for using those compositions and methods for treating diseases and conditions caused by a bacterial infection. More specifically, the compositions and methods include treating a gram-negative bacterium with a gram-positive host that produces a polypeptide effective against the gram-negative bacterium.

The invention discloses a method of extracting mycobacterium tuberculosis DNA and a kit for rapidly and accurately detecting multiple drug resistance (MDR) of mycobacterium tuberculosis. The method includes: extracting DNA to be detected from a clinical sample, determining mycobacterium tuberculosis infection by utilization of fluorescence real-time quantification PCR, indentifying whether the mycobacterium tuberculosis is drug-resistant or not and identifying the drug-resistant bacterial strain causing infection, and finally determining the pathogen infection quantity. The method can be used for detecting the whole drug-resistant genes with 29 sites that are determined to cause tubercle bacillus resistance to drugs (comprising rifampicin, isoniazide and ethambutol), and is the most comprehensive rapid molecular diagnosis system comprising tubercle bacillus drug-resistant genes so far. Through unique primers, probes and selection of fluorochrome marking designs, all the drug-resistant gene sites are detected by application of multiple qPCR. The application is simple, convenient and rapid. The results are accurate and reliable. The method and the kit have great practical value and wide application prospects for rapidly diagnosing tubercle bacillus infection and determining drug resistance, thus performing targeted treatment.

The disclosure provides compounds and methods to treat bacterial pathogenesis, and demonstrates that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.

The present invention discloses a supercritical CO2 extraction and silica gel column chromatographic process for extracting, separating and refining 1'-acetoxy chavicol acetic ester with activity of resisting tubercle bacillus infection from dried galangal rhizome as one kind of Zingiberaceae plant.

The Invention relates to materials and methods for the treatment of conditions associated with bacterial biofilms, intracellular bacterial infections and/or adherent-invasive Escherichia coli infections, including Crohns' disease. In particular, the invention relates to the use of colicins and bacteria producing colicins, for the treatment of such conditions.

The invention provides compositions and methods for preventing a metabolic disorder or bacterial infection in a subject, the composition comprising a bacterial endotoxin.

The invention provides a preparation method of a derivative of an antimicrobial peptide derived from Gekko sp. for treating Mycobacterium tuberculosis infection, belonging to the field of biomedicine. The antimicrobial peptide derivative is a single chain polypeptide synthesized from a natural polypeptide isolated from Chinese amphibian Gekko sp. The primary complete sequence of the polypeptide is: Val-Ser-Asn-Ala-Ala-Thr-His-Leu-Cys-Lys-His-Ala-His-Cysteine-His-Phe-Arg-Asp-Val-Cys-His-Asn-Trp-Met-Arg-His-Phe-Thr-Cys-Arg (NH2-VSNAATH LCKH AHC HF RDVCHNW MRHFTCR-COOH). The inventive antimicrobial peptide derivative can remarkably inhibit the growth of Mycobacterium tuberculosis including multi-drug resistant strains, and can be used in preparing drugs for treating infection of Mycobacterium tuberculosis including multi-drug resistant strains.

The invention discloses a mycobacterium tuberculosis EEC fusion protein. The amino acid sequence of the fusion protein is SEQ ID NO.8 in a sequence table; polynucleotide for encoding the polypeptide is shown as SEQ ID NO.7 in the sequence table; and the fusion protein contains a carrier of the polynucleotide and host cells. The invention further relates to preparation of the fusion protein, and effects of the fusion protein in tuberculosis auxiliary diagnosis, tubercle bacillus infection screening and tuberculosis vaccine development.

The present invention discloses a polypeptide with tubercle bacillus immunogenicity, which contains a sequence shown by Seq ID No.2 in the sequence table. The present invention also discloses an ELISPOT method, which utilizes the polypeptide to detect if a biological sample is infected with tubercle bacillus, and an agent box containing the polypeptide. When the polypeptide, the method and the agent box are adopted to detect the infectivity of tubercle bacillus, the false positive rate is greatly decreased, while the true positive rate can be kept unchanged.

The main objective of the present invention is to develop an herbal formulation with high polyphenol concentrations. A therapeutic effect of ingredients in herbal composition with Antioxidants, Anti-inflammatories, Anti Viral & Anti Microbial properties to reduce Oxidative Stress, Inflammation, Viral and Microbial Infections. The herbal composition promotes management of diabetes, regulation of cholesterol, also immune system processes that helps to fight against viral and bacterial infections, colds, or the flu, skin ailments such as Psoriasis & eczema. Herbal Composition comprises synergistic combination of Moringa Oleifera Leaf Powder, Spirulina & Aqueous extracts of Oregano Vulgare Leaf Extract, Shilajit extract, Rosemary Leaf extract, Pomegranate Fruit Preel extract, Amla fruit extract, Fenugreek Seed Extract, Curcumin Extract, Piperine extract. Therefore, the chosen herbal blend provides the body with all of the vitamins, minerals, and nutrients it needs to continuously boost health.

The invention relates to a gene chip detection method for detecting tubercle bacillus infection from a clinical specimen. The gene chip detection method is used for detecting small RNA (Ribonucleic Acid) of tubercle bacillus in the clinical specimen. The method comprises the following steps: 1, extracting total RNA in the clinical specimen; 2, performing reverse transcription by taking the total RNA extracted in the step 1 to synthesize cDNA (complementary Deoxyribonucleic Acid) and marking; 3, detecting the marked cDNA synthesized in the step 2 by using a gene chip.

The invention provides a preparation method of a derivative of an antimicrobial peptide derived from Gekko sp. for treating Mycobacterium tuberculosis infection, belonging to the field of biomedicine. The antimicrobial peptide derivative is a single chain polypeptide synthesized from a natural polypeptide isolated from Chinese amphibian Gekko sp. The primary complete sequence of the polypeptide is: Val-Asn-Asn-Gly-Gly-Ser-Cys-Leu-Cys-Glu-His-Ile-His-Leu-Ile-Arg-Gly-Val-Cys-His-His-Leu-Met-Arg-Cys-Tyr-Ile-Lys-Arg (NH2-VNNGGS CLCEHIHLIRGVCHHLMRCYIKR-COOH). The inventive antimicrobial peptide derivative can remarkably inhibit the growth of Mycobacterium tuberculosis including multi-drug resistant strains, and can be used in preparing drugs for treating infection of Mycobacterium tuberculosis including multi-drug resistant strains.

The invention relates to a reverse transcription polymerase chain reaction (PCR) method for detecting tubercle bacillus infection from a clinical specimen. The PCR detection method is used for detecting small RNA (Ribonucleic Acid) of tubercle bacillus in the clinical specimen. The method comprises the following steps: 1, extracting total RNA in the clinical specimen; 2, performing reverse transcription by taking the total RNA extracted in the step 1 to synthesize cDNA (complementary Deoxyribonucleic Acid); 3, performing PCR detection aiming at a tubercle bacillus small RNA detection primer and cDNA synthesized in the step 2.

The invention discloses an application of Myriberine A in preparing antituberculous medicines. The application of the Myriberine A aims at current situations that high tuberculosis incidence and appearance of multi-drug resistant strains of tubercle bacillus result in the rising tendency in the incidence and mortality rate of the tuberculosis, and the Myriberine A is found to have remarkable tubercle bacillus inhibitory activity and a good application prospect. The application of the Myriberine A in preparing the antituberculous medicines is disclosed for the first time. The framework type is a brand-new framework type, and therefore the Myriberine A has unexpected tubercle bacillus inhibitory activity. The Myriberine A has prominent substantive features and is impossibly revealed by other compounds, and has remarkable progresses when used for preventing and treating tubercle bacillus infection.

The invention discloses application of gypensapogenin A to preparation of anti-tubercle bacillus drugs. According to the high tubercle bacillus morbidity and the emergence of mycobacterium tuberculosis multiple-resistant strain, the tubercle bacillus morbidity and mortality are one the rise; and gypensapogenin A has remarkable tubercle bacillus suppression activity and good application prospect. The application of gypensapogenin A to the preparation of the anti-tubercle bacillus drugs is firstly publicized, the skeleton type is brand-new, the tubercle bacillus suppression activity is unexpectedly strong and the possibility of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in the prevention and treatment of the tubercle bacillus infection is made at the same time.

The present invention relates to the use of a strain of a mycobacterium of the Mycobacterium tuberculosis complex, into which an mspA gene capable of expressing a Mycobacterium smegmatis porin A has been inserted, for producing a vaccine for the prevention of an infection by a bacterium of the Mycobacterium tuberculosis complex in a host comprising eukaryotic cells, preferably macrophages, wherein said mycobacterial strain thus transformed exhibits reduced growth in said eukaryotic cells.

Pseudomonas aeruginosa flagellin protein recruits the mammalian host sialidase enzyme neuraminidase-1 (NEU1) to remove sialic acid residues from the extracellular domain of the mammalian cell-surface protein MUC1 (MUC1-ED), thereby exposing a cryptic binding site on the MUC1-ED protein backbone for flagellin binding. NEU1-driven MUC1-ED desialylation rapidly increases P. aeruginosa adhesion to the airway epithelium. MUC1-ED desialylation also increases MUC1-ED cleavage and shedding from the cell surface, where desialylated, shed MUC1-ED competitively blocks P. aeruginosa adhesion to cell-associated MUC1-ED. Presented herein are data showing that exogenously-administered, deglycosylated MUC1-ED peptides reduced adhesion of P. aeruginosa to airway epithelial cells. Also presented are data showing that administration of P. aeruginosa to mice in combination with deglycosylated MUC1-ED decreased P. aeruginosa recovered from the lungs at 48 hr and 72 hr post-infection. Such findings are extended to the methods of treatment and prevention of bacterial infections defined herein.